Vor Biopharma (VOR) Stock Price, News & Analysis

Company Overview

Vor Biopharma is a clinical‐stage biotechnology company dedicated to developing allogeneic, or “off‐the‐shelf,” cell therapies for patients with hematologic malignancies. The company leverages gene‐editing technologies to engineer healthy donor hematopoietic stem cells that are resistant to targeted anti‐cancer therapies, enabling potent elimination of malignant cells while sparing normal blood cell precursors.

The company’s proprietary platform focuses on knocking out specific cell surface antigens in donor stem cells, creating paired therapeutic regimens in which one agent selectively clears malignant cells expressing the target antigen and the gene‐edited cells then repopulate the bone marrow. Vor Biopharma’s lead candidate, VOR33, is designed to protect normal hematopoiesis from anti-CD33 therapies in acute myeloid leukemia, and is being advanced in clinical trials. Additional pipeline programs aim to address other myeloid antigens and leverage similar complementary logic approaches to treat a range of blood cancers.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Vor Biopharma operates its research and development activities from the heart of one of the world’s leading biotech hubs. The company is led by President and Chief Executive Officer Martin W. Babler, Ph.D., whose experience in cell therapy and gene editing supports Vor Biopharma’s mission to deliver curative cell therapies that address critical unmet needs in hematology.

Key Stats

• Today's Range: $1.80 to $1.98
• 50-Day Range: $1.45 to $2.67
• 52-Week Range: $0.13 to $3.29
• Volume: 6.00 million shs
• Average Volume: 7.65 million shs
• Market Capitalization: $228.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.07
• Consensus Rating: Moderate Buy

Vor Biopharma Stock Analysis - MarketRank™

Vor Biopharma scored higher than 41% of companies evaluated by MarketBeat, and ranked 677th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vor Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.

Upside Potential

Vor Biopharma has a consensus price target of $6.07, representing about 230.6% upside from its current price of $1.84.

Amount of Analyst Coverage

Vor Biopharma has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vor Biopharma are expected to grow in the coming year, from ($1.42) to ($1.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vor Biopharma is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vor Biopharma is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for VOR.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vor Biopharma does not currently pay a dividend.

Dividend Growth

Vor Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for VOR.

News and Social Media

• Score: 1.0 / 5
• News Sentiment: -0.29

News Sentiment

Vor Biopharma has a news sentiment score of -0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Vor Biopharma this week, compared to 2 articles on an average week.

Search Interest

Only 15 people have searched for VOR on MarketBeat in the last 30 days. This is a decrease of -6% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Vor Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Vor Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,034,010.00 in company stock.

Percentage Held by Insiders

Only 0.45% of the stock of Vor Biopharma is held by insiders.

Percentage Held by Institutions

97.29% of the stock of Vor Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VOR Stock Analysis - Frequently Asked Questions

How have VOR shares performed this year?

Vor Biopharma's stock was trading at $1.11 on January 1st, 2025. Since then, VOR shares have increased by 65.3% and is now trading at $1.8350.

How were Vor Biopharma's earnings last quarter?

Vor Biopharma Inc. (NYSE:VOR) announced its earnings results on Thursday, November, 7th. The company reported ($0.40) earnings per share for the quarter, meeting the consensus estimate of ($0.40).

When did Vor Biopharma IPO?

Vor Biopharma (VOR) raised $150 million in an initial public offering on Friday, February 5th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Goldman Sachs, Evercore ISI, Barclays and Stifel acted as the underwriters for the IPO.

Who are Vor Biopharma's major shareholders?

Vor Biopharma's top institutional shareholders include Eisler Capital Management Ltd., LMR Partners LLP, Jane Street Group LLC and XTX Topco Ltd (0.03%).
View institutional ownership trends.

How do I buy shares of Vor Biopharma?

Shares of VOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vor Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vor Biopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Ford Motor (F), Pfizer (PFE), Bank of America (BAC) and General Motors (GM).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 9/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological Products, Except Diagnostic Substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:VOR
• CIK: 1817229
• Web: www.vorbiopharma.com
• Phone: 617-655-6580
• Fax: N/A
• Employees: 140
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Vor Biopharma: $6.07
• High Price Target: $14.00
• Low Price Target: $0.40
• Potential Upside/Downside: +201.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 126,683,000
• Free Float: 65,446,000
• Market Cap: $254.63 million
• Optionable: Not Optionable
• Beta: 2.05